Valeant secures financing for potential Salix bid: Bloomberg

Thu Feb 12, 2015 3:48pm EST
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

(Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO: Quote) (VRX.N: Quote) has arranged financing for a potential bid for bowel-drug maker Salix Pharmaceuticals Ltd SLXP.O, Bloomberg reported, citing people familiar with the matter.

The acquisitive Canadian drugmaker will likely bid more than $150 per share for the company, Bloomberg said, quoting one of those people. (bloom.bg/16YHzmJ)

A bid of $150 per share would value Salix at about $9.6 billion. Salix's stock was up 4.6 percent at $149.82 in afternoon trading on the Nasdaq on Thursday.

Up to Wednesday's close, the company's stock had risen 7 pct since Feb. 3 when Bloomberg first reported that Valeant was weighing a bid for the company. (bloom.bg/1Da0N5B)

Salix, based in Raleigh, North Carolina, was not immediately available for comment. A Valeant spokeswoman said the company does not respond to market rumors or speculation.

Bloomberg, citing sources, reported earlier this month that British drugmaker Shire Plc (SHP.L: Quote) SLXP.O was also interested in Salix. (bloom.bg/1Da0N5B)

Valeant, which lost a takeover contest for Allergan Inc last year, said earlier this week that it would buy bankrupt cancer vaccine maker Dendreon corp DNDNQ.PK for about $400 million.

Valeant's U.S.-listed shares were up about 1.9 percent at $167.45 on the New York Stock Exchange. The company's Canadian shares were up about 0.6 percent at C$209.

(Reporting by Natalie Grover; Editing by Ted Kerr)

 
The head offices of Valeant Pharmaceuticals International Inc. are seen in Laval, Quebec May 20, 2014. REUTERS/Christinne Muschi